Clinical Trials Browser

Phase 1 × Not yet recruiting × ibrutinib × Clear all

NCT07169565 2025-09-11

Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia

Phase 1 Not yet recruiting

Waldenstrom Macroglobulinemia